1. Home
  2. CHMI vs KPTI Comparison

CHMI vs KPTI Comparison

Compare CHMI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cherry Hill Mortgage Investment Corporation

CHMI

Cherry Hill Mortgage Investment Corporation

HOLD

Current Price

$2.64

Market Cap

83.3M

Sector

Real Estate

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$7.09

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHMI
KPTI
Founded
2012
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
94.6M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
CHMI
KPTI
Price
$2.64
$7.09
Analyst Decision
Hold
Strong Buy
Analyst Count
3
6
Target Price
$2.75
$22.17
AVG Volume (30 Days)
221.1K
199.6K
Earning Date
11-06-2025
11-03-2025
Dividend Yield
15.21%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$40,202,000.00
$142,530,000.00
Revenue This Year
N/A
$3.82
Revenue Next Year
$31.73
$3.18
P/E Ratio
$140.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.17
$3.51
52 Week High
$3.68
$12.45

Technical Indicators

Market Signals
Indicator
CHMI
KPTI
Relative Strength Index (RSI) 68.02 60.74
Support Level $2.47 $5.99
Resistance Level $2.62 $7.48
Average True Range (ATR) 0.06 0.53
MACD 0.02 0.06
Stochastic Oscillator 92.96 72.48

Price Performance

Historical Comparison
CHMI
KPTI

About CHMI Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: